CLINICAL_TRIALS
trial_result
· 2016-03-31
Clinical Trial Update: Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43 [Phase 2, Phase 3]
Summary
A confirmatory Phase II/III trial evaluating the IC43 vaccine for Pseudomonas aeruginosa infection has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Valneva Austria GmbH | Conditions: Pseudomonas Aeruginosa Infection | Phase 2, Phase 3 | Status: COMPLETED